Followers | 826 |
Posts | 119567 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Friday, February 16, 2018 5:46:22 PM
[Miscellaneous updates.]
Proprietary autoimmune program
• 1H18: Start phase-1 trial of M230, which is partnered with CSL (#msg-127656306).
• 2018: Report full dataset from M281 phase-1 trial at an unspecified medical conference. (Top-line data were reported in Jan 2018: #msg-137491062.)
• 2018 Start phase-1 trial of M254, a hyper-sialylated IVIG.
FoB program
• Timing unknown: M923 (Humira FoB) partnership or divestiture.
• 1H18: Start phase-3 trial for M710 (Eylea FoB).
• 2018: Report reason for inability of M834 (Orencia FoB) to meet its phase-1 pharmacokinetic endpoint; start phase-1 do-over, if necessary.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM